Fujino Toshio

フジノトシオ | Fujino Toshio

Affiliation and department：
Job title： Postdoctoral Research Fellow

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (7)： Lung cancer , Targeted therapy , MET , ALK , EGFR , ROS1 , KRAS

Research theme for competitive and other funds (4)：

2022 - 2026 Elucidation and Overcoming the Primary Resistance Mechanism in MET-driven Lung Cancer
2021 - 2023 Analysis of CBL gene mutations as a novel therapeutic target for lung cancer
2019 - 2021 Development of new treatment strategy for lung cancer haboring MET exon14 mutation
2016 - 2019 Molecular targeted therapy against adenocarcinoma of the lung harboring MET exon 14 skipping mutation

Papers (136)：

Jessica J. Lin, Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson, Benjamin Besse, D. Ross Camidge, Toshio Fujino, Satoshi Yoda, et al. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discovery. 2024
Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, et al. Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023
Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, et al. Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing. JTO clinical and research reports. 2023. 4. 9. 100554-100554
Sun Min Lim, Toshio Fujino, Chulwon Kim, Gwanghee Lee, Yong-Hee Lee, Dong-Wan Kim, Jin Seok Ahn, Tetsuya Mitsudomi, Taiguang Jin, Sang-Yoon Lee. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023. 29. 16. 3004-3016
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. Journal of hematology & oncology. 2022. 15. 1. 79-79

ｍore...

MISC (62)：

Kenichi Suda, Isao Murakami, Keiko Obata, Toshio Fujino, Kazuko Sakai, Junichi Soh, Kazuto Nishio, Tetsuya Mitsudomi. Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd-generation EGFR-TKIs in lung cancer. CANCER SCIENCE. 2021. 112. 444-444
小原秀太, 須田健一, 藤野智大, 古賀教将, 西野将矢, 浜田顕, 千葉眞人, 武本智樹, 宗淳一, 光冨徹哉, et al. Next-generation sequencing(NGS)を用いたctDNAの外科切除症例における再発予測因子としての意義. 肺癌(Web). 2020. 60. 2
濱田顕, 須田健一, 小原秀太, 藤野智大, 古賀教将, 西野将矢, 千葉眞人, 武本智樹, 宗淳一, 塩野知志, et al. 第8版Stage分類の妥当性と問題点 IA期非小細胞肺がんの予後は腫瘍径よりGGO成分の有無に依存する. 肺癌. 2019. 59. 6. 565-565
武本智樹, 小原秀太, 藤野智大, 古賀教将, 西野将矢, 濱田顕, 千葉眞人, 須田健一, 宗淳一, 光冨徹哉. 早期社会復帰を目指したチーム医療の取り組み胸部手術患者における早期社会復帰を目指した訪問看護ステーションとの連携. 肺癌. 2019. 59. 6. 591-591
古賀教将, 須田健一, 小原秀太, 藤野智大, 西野将矢, 濱田顯, 千葉眞人, 武本智樹, 宗淳一, 光冨徹哉. Occultリンパ節転移の予測因子に関する検討. 肺癌. 2019. 59. 6. 679-679

ｍore...

Patents (1)：

Drugs for lung cancer that has acquired resistance to type I TKIs.

Books (4)：

Respiratory Medicine
2022
Respiratory Journal
2020
PROGRESS IN MEDCINE
lifescience 2018 ISBN:9784898016374
検診胸部X線写真の読影
国際医学出版 2016 ISBN:4861022630

Lectures and oral presentations (8)：

Preclinical Activity of NVL-655 in Patient-Derived Models of ALK Cancers, Including Those with Lorlatinib-Resistant G1202R/L1196M Compound Mutation
(EORTC-NCI-AACR 2022 2022)
Proposal of foretinib as second-line TKI after capmatinib/tepotinib treatment failure in NSCLC with MET exon14 mutation.
(IASLC 2022 World Conference on Lung Cancer 2022)
Treatment strategy of lung cancer with MET, NTRK and BRAF gene aberrations: Insights from in vitro and clinical data
(2022 the Japanese Society of Medical Oncology Annual Meeting 2022)
Comprehensive analysis of secondary mutation as resistance mechanism to seven MET-TKIs for MET exon 14 skipping in vitro
(2019)
In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping
(19th World Conference on Lung Cancer 2018)

ｍore...

Education (2)：

2017 - 2020 Kindai University Faculty of Medicine Graduate School of Medical Sciences
2006 - 2012 Nagoya City University

Work history (5)：

2022/04 - 現在 Massachusetts General Hospital Cancer Center Research fellow
2017/04 - 2022/03 Kindai University Faculty of Medicine Thoracic Surgery
2017/01 - 2017/03 Nagoya City University Thoracic Surgery
2014/04 - 2016/12 Seirei Mikatahara General Hospital Thoracic Surgery
2012/04 - 2014/03 Ijinkai Takeda General Hospital

Awards (7)：

2022/04 - Takeda Science Foundation Research grant for Study Abroad
2022/04 - 日本呼吸機学会リリー・オンコロジー・フェローシップ・プログラム
2020/11 - The Japan Lung Cancer Society Young Scientist Award
2020/07 - Kindai University Medical Society Award
2020/03 - Kindai University Kindai University President Award

Show all

Association Membership(s) (10)：

The Japanese Respiratory Society , IASLC , ASCO , THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY , THE JAPAN LUNG CANCER SOCIETY , THE JAPANESE ASSOCIATION FOR THORACIC SURGERY , The Japanese Association for Chest Surgery , JAPAN SURGICAL SOCIETY , THE JAPANESE CANCER ASSOCIATION , THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page